Logo image of CMBM

CAMBIUM NETWORKS CORP (CMBM) Stock Fundamental Analysis

NASDAQ:CMBM - Nasdaq - KYG177661090 - Common Stock - Currency: USD

0.94  -0.1 (-9.62%)

Fundamental Rating

2

Overall CMBM gets a fundamental rating of 2 out of 10. We evaluated CMBM against 48 industry peers in the Communications Equipment industry. The financial health of CMBM is average, but there are quite some concerns on its profitability. CMBM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CMBM had negative earnings in the past year.
In the past year CMBM has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: CMBM reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: CMBM reported negative operating cash flow in multiple years.
CMBM Yearly Net Income VS EBIT VS OCF VS FCFCMBM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M -60M

1.2 Ratios

The Return On Assets of CMBM (-44.08%) is worse than 85.42% of its industry peers.
CMBM has a worse Return On Equity (-224.89%) than 85.42% of its industry peers.
Industry RankSector Rank
ROA -44.08%
ROE -224.89%
ROIC N/A
ROA(3y)-3.98%
ROA(5y)-2.62%
ROE(3y)-16.13%
ROE(5y)-12.63%
ROIC(3y)N/A
ROIC(5y)N/A
CMBM Yearly ROA, ROE, ROICCMBM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40 -60 -80

1.3 Margins

With a Gross Margin value of 17.14%, CMBM is not doing good in the industry: 91.67% of the companies in the same industry are doing better.
CMBM's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CMBM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.52%
GM growth 5Y-8.13%
CMBM Yearly Profit, Operating, Gross MarginsCMBM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

More info and screens

4

2. Health

2.1 Basic Checks

CMBM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CMBM has been increased compared to 1 year ago.
The number of shares outstanding for CMBM has been increased compared to 5 years ago.
Compared to 1 year ago, CMBM has a worse debt to assets ratio.
CMBM Yearly Shares OutstandingCMBM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CMBM Yearly Total Debt VS Total AssetsCMBM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -0.96, we must say that CMBM is in the distress zone and has some risk of bankruptcy.
CMBM has a worse Altman-Z score (-0.96) than 72.92% of its industry peers.
There is no outstanding debt for CMBM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.96
ROIC/WACCN/A
WACC10.04%
CMBM Yearly LT Debt VS Equity VS FCFCMBM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

CMBM has a Current Ratio of 1.10. This is a normal value and indicates that CMBM is financially healthy and should not expect problems in meeting its short term obligations.
CMBM has a worse Current ratio (1.10) than 79.17% of its industry peers.
CMBM has a Quick Ratio of 1.10. This is a bad value and indicates that CMBM is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CMBM (0.82) is worse than 79.17% of its industry peers.
Industry RankSector Rank
Current Ratio 1.1
Quick Ratio 0.82
CMBM Yearly Current Assets VS Current LiabilitesCMBM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CMBM have decreased strongly by -1047.37% in the last year.
CMBM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.89%.
Measured over the past years, CMBM shows a decrease in Revenue. The Revenue has been decreasing by -1.85% on average per year.
EPS 1Y (TTM)-1047.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.18%
Revenue 1Y (TTM)-34.89%
Revenue growth 3Y-7.53%
Revenue growth 5Y-1.85%
Sales Q2Q%1.58%

3.2 Future

Based on estimates for the next years, CMBM will show a very strong growth in Earnings Per Share. The EPS will grow by 22.05% on average per year.
The Revenue is expected to grow by 0.03% on average over the next years.
EPS Next Y9.84%
EPS Next 2Y43.02%
EPS Next 3Y22.05%
EPS Next 5YN/A
Revenue Next Year-20.96%
Revenue Next 2Y-3.53%
Revenue Next 3Y0.03%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CMBM Yearly Revenue VS EstimatesCMBM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M
CMBM Yearly EPS VS EstimatesCMBM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 1 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CMBM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 18.43, which indicates a rather expensive current valuation of CMBM.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CMBM indicates a somewhat cheap valuation: CMBM is cheaper than 62.50% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of CMBM to the average of the S&P500 Index (37.67), we can say CMBM is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 18.43
CMBM Price Earnings VS Forward Price EarningsCMBM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMBM Per share dataCMBM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CMBM does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as CMBM's earnings are expected to grow with 22.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.02%
EPS Next 3Y22.05%

More info and screens

0

5. Dividend

5.1 Amount

CMBM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAMBIUM NETWORKS CORP

NASDAQ:CMBM (7/25/2025, 8:00:00 PM)

0.94

-0.1 (-9.62%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryCommunications Equipment
Earnings (Last)05-29 2025-05-29/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners21.68%
Inst Owner Change0.78%
Ins Owners3.7%
Ins Owner Change-0.49%
Market Cap26.55M
Analysts82.86
Price Target5.1 (442.55%)
Short Float %13.98%
Short Ratio0.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.63%
Min EPS beat(2)-15.61%
Max EPS beat(2)18.88%
EPS beat(4)1
Avg EPS beat(4)-57.09%
Min EPS beat(4)-139.74%
Max EPS beat(4)18.88%
EPS beat(8)3
Avg EPS beat(8)-82.13%
EPS beat(12)7
Avg EPS beat(12)3.73%
EPS beat(16)11
Avg EPS beat(16)9.26%
Revenue beat(2)0
Avg Revenue beat(2)-3.75%
Min Revenue beat(2)-5.39%
Max Revenue beat(2)-2.12%
Revenue beat(4)0
Avg Revenue beat(4)-5.07%
Min Revenue beat(4)-8.54%
Max Revenue beat(4)-2.12%
Revenue beat(8)1
Avg Revenue beat(8)-5.94%
Revenue beat(12)3
Avg Revenue beat(12)-3.54%
Revenue beat(16)6
Avg Revenue beat(16)-2.28%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)6.67%
EPS NQ rev (3m)6.67%
EPS NY rev (1m)1%
EPS NY rev (3m)1%
Revenue NQ rev (1m)0.5%
Revenue NQ rev (3m)0.5%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 18.43
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 1.92
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)0.05
Fwd EY5.43%
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS6.1
BVpS1.54
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.08%
ROE -224.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.14%
FCFM N/A
ROA(3y)-3.98%
ROA(5y)-2.62%
ROE(3y)-16.13%
ROE(5y)-12.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.52%
GM growth 5Y-8.13%
F-Score2
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 128.96%
Cap/Sales 7.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.1
Quick Ratio 0.82
Altman-Z -0.96
F-Score2
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)130.65%
Cap/Depr(5y)120.32%
Cap/Sales(3y)3.75%
Cap/Sales(5y)3.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1047.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.18%
EPS Next Y9.84%
EPS Next 2Y43.02%
EPS Next 3Y22.05%
EPS Next 5YN/A
Revenue 1Y (TTM)-34.89%
Revenue growth 3Y-7.53%
Revenue growth 5Y-1.85%
Sales Q2Q%1.58%
Revenue Next Year-20.96%
Revenue Next 2Y-3.53%
Revenue Next 3Y0.03%
Revenue Next 5YN/A
EBIT growth 1Y-733.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-58.16%
EBIT Next 3Y65.62%
EBIT Next 5YN/A
FCF growth 1Y-105.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-595.46%
OCF growth 3YN/A
OCF growth 5YN/A